Tiziana Life Sciences is a Nasdaq listed company with a goal to help sufferers of neuroinflammatory diseases. These include Non-active, secondary progressive multiple sclerosis, Alzheimer's this includes being used alongside recent approvals where neuroinflammation is still present, ALS, Long Covid, T1D. We also have promising pre clinical studies in ICH and TBI. We have an ongoing expanded access program where we have human data in SPMS before we opened our phase 2 trial in this indication. PET imaging from this EA program shows considerable reduction in microglia activity.